Introduction
============

Non-alcoholic fatty liver disease (NAFLD) refers to the excessive accumulation of liver fat according to a histological analysis identifying fatty degeneration in \>5% of hepatocytes or a fat fraction density \>5.6%, as evaluated by proton magnetic resonance spectroscopy (1H-MRS) or quantitative fat/water selective magnetic resonance imaging (MRI), that leads to subsequent liver injury, balloon-like degeneration, and chronic inflammatory infiltration with or without fibrosis and without excessive alcohol intake (male, \<30 g/day, female \<20 g/day) or other known causes. NAFLD includes non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH) ([@b1-ijmm-44-06-2201],[@b2-ijmm-44-06-2201]) and has become an epidemic chronic liver disease worldwide ([@b3-ijmm-44-06-2201]). However, no specific therapeutic drugs have been developed following decades of research. The reason for this may be related to several factors, such as the long latency of NAFLD, an incomplete understanding of the pathogenesis of NAFLD ([@b4-ijmm-44-06-2201],[@b5-ijmm-44-06-2201]), and the involvement of multiple factors. Further exploration of the molecular mechanisms of NAFLD will contribute to the future development of drugs for the treatment of NAFLD.

The WNT signaling pathway has been classified into the classical and non-classical pathways according to whether the accumulation of β-catenin in the nucleus is necessary or not. The classical WNT/β-catenin signaling pathway has been recognized as a key regulator of adipose differentiation and exerts anti-lipid formation and anti-inflammatory effects. By contrast, the non-classical WNT signaling pathway promotes fat formation, lipid accumulation and inflammation. An imbalance in the WNT signaling pathways has been closely associated with NAFLD. When the classical WNT/β-catenin signaling pathway is activated, the expression of CCAAT enhancer binding protein α (C/EBP-α) and peroxisome prolif-erator activated receptor γ (PPAR-γ) is inhibited by β-catenin, which in turn inhibits the differentiation of preadipocytes ([Fig. 1](#f1-ijmm-44-06-2201){ref-type="fig"}) ([@b4-ijmm-44-06-2201]). A mutation in low-density lipoprotein-related receptor 6 (LRP6; LRP6^R611C^), a common coreceptor of the classical WNT/β-catenin signaling pathway, induces lipid accumulation in the liver through the nutritional sensory pathway \[insulin-like growth factor 1 (IGF1)/AKT/mammalian target of rapamycin (mTOR)/sterol regulatory element-binding transcription factor (*SREBP)1/2*\] ([Fig. 1](#f1-ijmm-44-06-2201){ref-type="fig"}). Homozygotic LRP6^R611C^ (LRP6^mut/mut^) mice have been shown to exhibit NASH with fibrosis ([@b6-ijmm-44-06-2201],[@b7-ijmm-44-06-2201]). Wnt3a is a canonical Wnt ligand ([@b4-ijmm-44-06-2201]). As an inhibitor of inflammatory processes, the Wnt3a inhibition of the non-canonical Wnt pathway reduces lipid accumulation and inflammation, but has almost no effect in enhancing the canonical Wnt pathway ([@b7-ijmm-44-06-2201]). Along with reducing the influence of the risk factors of NAFLD, it is reasonable to believe that inhibiting the classical WNT/β-catenin regulatory signaling pathway is indispensable in promoting the pathogenesis of NAFLD, and this may be achieved by upregulating PPAR-γ and *SREBP1c*.

MicroRNAs (miRNAs or miRs) are a class of endogenous, single-stranded, non-coding small RNAs with a length of \~19-25 nucleotides that regulate gene expression by inhibiting translation, promoting the cleavage of mRNAs or targeting promoter regions ([@b8-ijmm-44-06-2201]). *miR-21* was one of the earliest discovered human miRNAs. In the pathogenesis of NAFLD, *miR-21* has been shown to participate in liver lipid metabolism through a variety of targets, including fatty acid binding protein 7 (FABP7) and 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), and to contribute to NASH via peroxi-some proliferator activated receptor *α* (PPAR-α). It can also participate in NAFLD through SMAD7, phosphate and tension homolog (PTEN), HMG-box transcription factor 1D (HBP1D) and other targets ([@b8-ijmm-44-06-2201]-[@b13-ijmm-44-06-2201]). Moreover, our research group previously demonstrated that the expression of LRP6 was inhibited in HepG2 cells transfected with a *miR-21* mimic and that LRP6 was a target of *miR-21*. We also observed that the synthesis of triglycerides was decreased through the inhibition of *miR-21* through RNA interference, suggesting that *miR-21* may be involved in lipid synthesis and metabolism by interacting with the WNT/β-catenin signaling pathway to further participate in the pathogenesis and pathology of NAFLD ([@b14-ijmm-44-06-2201]). This was the first time, to the best of our knowledge, that *miR-21* was linked to the WNT/β-catenin signaling pathway. Therefore, in order to explore the regulatory role of *miR-21* in the WNT/β-catenin signaling pathway in NAFLD in mice, the objective of this study was to explore the role of the molecular regulatory network of *miR-21* in the pathogenesis of NAFLD and to elucidate the pathological mechanisms underlying NAFLD.

Materials and methods
=====================

Mouse model
-----------

All mice were male *C57BL/6J* mice (6 weeks old, n=15, 22.60±1.24 g, purchased from Chengdu Dashuo Laboratory Animal Co., Ltd.; <http://www.cd-dossy.cn/>) that were bred at the Laboratory Animal Center of Southwest Medical University (<http://dwzx.swmu.edu.cn/>) and allowed to acclimatize to their environment for 1 week. All animals received care according to the guidelines of the Institutional Animal Care and Use Committee of Southwest Medical University (Luzhou, China), and the experiment was approved by the Experimental Animal Ethics Committee of Southwest Medical University (application acceptance no. 20180521-11). C57BL/6J mice (n=9) were fed a methionine- and choline-deficient diet (MCD, Trophic Animal Feed High-Tech Co., Ltd., <http://www.trophic.cn/>) to establish NAFLD; after 4 weeks, 3 mice (15.03±0.75 g) without manifestations of peritonitis were sacrificed by cervical dislocation following an intraperitoneal injection of 10% chloral hydrate (400 mg/kg), and the liver tissues were removed for hematoxylin & eosin (H&E) staining to confirm the successful establishment of the model. Subsequently, the remaining mice were divided into 2 groups of 3 mice in each. Antagomir-21 (antagomir-21 group, n=3, 8 mg/kg 5-UCA ACA CUG UCU GUA GAU CUA-3 ([@b10-ijmm-44-06-2201]), purchased from Shanghai Genepharma Pharmaceutical Technology Co. Ltd., <http://www.genepharma.bioon.com.cn/>) or the same dose of saline (control group, n=3), was injected through the tail vein at 15 weeks of age once a day for 3 consecutive days. The C57BL/6J wild-type mice (normal group, n=6) were fed a methionine- and choline-sufficient diet (MCS, Trophic Animal Feed High-Tech Co. Ltd., <http://www.trophic.cn/>). After 4 weeks, 3 mice (26.7±0.76 g) without manifestations of peritonitis were randomly selected, anesthetized and sacrificed (using the same method as described above). The liver tissues were removed for H&E staining as a NAFLD control. At 15 weeks of age, the same dose of saline was injected into the tail vein once a day for 3 consecutive days ([Fig. 2](#f2-ijmm-44-06-2201){ref-type="fig"}).

All mice without manifestations of peritonitis (antagomir-21 group, 12.63±0.72 g; control group, 13.4±0.69 g; normal group, 30.13±5.51 g) were anesthetized with 10% chloral hydrate (400 mg/kg) at the age of 19 weeks. Once the mice no longer exhibited a corneal reflex or pain responses, blood (\~0.5 ml) was collected from the eyeball and the heart through a needle inserted obliquely into the heart at a 45° angle (in the location with the most obvious heartbeat) to obtain blood. After collecting the blood, the mice died within 1 min from continuous cardiac arrest. The collected blood was allowed to settle for 30 min and centrifuged for 20 min at 2,500 x g at 4°C. The supernatant was collected following centrifugation and stored at -80°C for blood lipid and aminotransferase detection. The liver was separated quickly and weighed.

Approximately 400 mg of liver tissue were frozen and stored at -80°C for PCR and western blot analysis. Approximately 300 mg of liver tissue were fixed in 4% formaldehyde for H&E staining and immunohistochemical analysis.

Biochemical analysis
--------------------

The levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), triglycerides (TG), total cholesterol (TC) and low-density lipoprotein (LDL) were detected with the DR-200Bs enzyme labeling instrument (Diatek Co., <http://www.diateklab.com/>) according to the manufacturer\'s instructions (Nanjing Jiancheng Bioengineering Institute., <http://www.njjcbio.com/>).

Histological analysis
---------------------

Paraffin-embedded liver sections (3-*µ*m-thick) were stained with H&E (sent to the Department of Pathology, Affiliated Hospital of Southwest Medical University). The H&E-stained sections were observed under an optical microscope (Olympus, <http://www.olympus.com.cn/>). The NAS scores of the H&E-stained sections were determined by a pathologist who was blinded to the mouse groupings and according to the following criteria ([@b15-ijmm-44-06-2201]): i) Steatosis: 0-3 points, \<5, 5-33, 33-66 and ≥66%; ii) intralobular inflammation (counting of necrotic foci at x20 magnification): 0-3 points, none, \<2, 2-4, ≥4; and iii) hepatocyte ballooning degeneration change: 0-2 points, none, rare, more common. NASH was excluded by a score of 0-2; NASH could be considered based on a score of 3-4, and NASH would likely be diagnosed based on a score of 5-8.

Western blot analysis
---------------------

The liver tissues were rinsed 2-3 times with precooled PBS buffer to remove blood, cut into small sections, and placed in a homogenizer (Wuhan Aspen Biotechnology Co., Ltd.). A 10-fold volume of tissue protein extraction reagent (Wuhan Aspen Biotechnology Co., Ltd.) with protease inhibitor (Wuhan Aspen Biotechnology Co., Ltd.) was added and thoroughly homogenized, and the homogenate was incubated in an ice bath for 30 min. The supernatant protein concentration was determined by a BCA protein concentration assay kit (Wuhan Aspen Biotechnology Co., Ltd.) following centrifugation at 4°C and 13,000 x g for 5 min. The sample size was determined according to the sample concentration, and the total protein in each sample was 40 *µ*g. The protein samples were electrophoretically transferred onto PVDF membranes (Shanghai Millipore Filter Material Co., Ltd., <http://millipore.org.cn/search/>) after adding an appropriate amount of 5X protein sample buffer (Wuhan Aspen Biotechnology Co., Ltd.) and boiling the samples in a water bath at 95-100°C for 5 min, in which protein samples were separated using 8-10% SDS-PAGE and the percentage of Tween-20 in TBST was 0.1%. The PVDF membranes were activated with methanol prior to use. The membranes were sealed and incubated at room temperature for 1 h. The sealing fluid was removed, and the membranes were incubated with primary antibody overnight at 4°C. The diluted primary antibody ([Table I](#tI-ijmm-44-06-2201){ref-type="table"}) was recovered, and the membranes were washed 3 times with TBST for 5 min each time. The diluted secondary antibody ([Table II](#tII-ijmm-44-06-2201){ref-type="table"}) was added, and the membranes were incubated at room temperature for 30 min. The membranes were washed in TBST 4 times on a shaker at room temperature for 5 min each time. Freshly mixed ECL solution (Wuhan Aspen Biotechnology Co., Ltd.) was added onto the protein side of the membranes, and the membranes were exposed in a darkroom. The exposure conditions were adjusted to achieve different light intensities prior to developing the film. The photographic films (Eastman Kodak, <http://www.kodak.com.cn/>) were scanned into files, and the AlphaEaseFC software processing system (Alpha Innotech Corporation, <http://www.alphainnotech.com>) was used to analyze the optical density of the target bands.

RNA isolation and RT-qPCR analysis
----------------------------------

Total RNA was extracted from the liver tissues using a TRIzol reagent kit (Invitrogen™, Semerfly Technology Co., Ltd., <https://www.thermofisher.com/>), quantified by a SYBR^®^ Premix Ex Taq™ kit (Takara Biomedical Technology Co., Ltd., <http://www.takara.com.cn/>) according to the manufacturer\'s instructions and stored at -80°C. The first-strand cDNA of *miR-21* was synthesized using the M-MLV reverse transcriptase kit (Invitrogen™, Semerfly Technology Co., Ltd., <https://www.thermofisher.com/>) according to the manufacturer\'s protocol. The synthesis of the first-strand cDNA for other genes, such as *SREBP1c*, fatty acid synthase (*FAS*), adenosine 5-monophosphate (AMP)-activated protein kinase α (*AMPKα*) and carnitine palmitoyl transferase 1α (*CPT1α*), was performed using the PrimeScriptTM RT Reagent kit with gDNA Eraser (Takara Biomedical Technology Co., Ltd., <http://www.takara.com.cn/>) according to the manufacturer\'s protocol. The sequences of the primers are presented in [Table III](#tIII-ijmm-44-06-2201){ref-type="table"}. qPCR was performed on a Life Technologies StepOneTM Real-Time PCR instrument, and each sample was assayed by using 3 replicate wells with the SYBR^®^ Premix Ex TaqTM kit (Takara Biomedical Technology Co., Ltd., <http://www.takara.com.cn/>). The reaction procedure was as follows: Predenaturation, 95°C for 1 min; 40 cycles of 95°C, 15 sec → 58°C, 20 sec → 72°C, 45 sec; melting curve, 60°C → 95°C, 20 sec per 1°C of temperature. The reaction conditions were as follows: 2X qPCR Mix, 5.0 *µ*l; primer working dilution (2.5 *µ*M), 1.0 *µ*l; template, 1.0 *µ*l; ddH~2~O, 2.8 *µ*l; Rox, 0.2 *µ*l. The corresponding gene expression and relative mRNA expression were evaluated by the 2^-ΔΔCq^ method and the determination of the geometric mean ([@b16-ijmm-44-06-2201]).

Immunohistochemistry
--------------------

Paraffin-embedded sections were placed in a 65°C oven for 2 h, dewaxed in water, and washed 3 times with PBS (Wuhan Aspen Biotechnology Co., Ltd.) for 5 min each time. The slices were placed in EDTA buffer (Wuhan Aspen Biotechnology Co., Ltd. China) for microwave antigen retrieval, and the microwave was set at medium power until a boil was reached, after which it was set at low power until a boil was reached at intervals of 10 min. After allowing them to cool, the cells were washed with PBS 3 times for 5 min each time. The sections were placed in 3% hydrogen peroxide solution (Sinopharm Chemical Reagent Co., Ltd., <https://www.sinoreagent.com/>) and incubated for 10 min at room temperature in the dark. The sections were washed 3 times with PBS for 5 min each time and incubated in 5% BSA (Shanghai Roche Pharmaceutical Co., Ltd., <https://www.roche.com/>) for 20 min after drying. The BSA solution was removed, and \~50 *µ*l of diluted primary antibody ([Table IV](#tIV-ijmm-44-06-2201){ref-type="table"}) was added to each section to cover the tissue, which was incubated at 4°C overnight. After washing with PBS 3 times for 5 min each time, 50-100 *µ*l of secondary antibody for the corresponding species ([Table V](#tV-ijmm-44-06-2201){ref-type="table"}) was added to each section, which was incubated for 50 min at 37°C. The sections were then washed with PBS 3 times for 5 min each time. After removing the PBS solution, 50-100 *µ*l of freshly prepared DAB solution (Beijing Zhongshang Jinqiao Biotechnology Co., Ltd., <http://www.zsbio.com/>) was added to each section, and the color development was controlled under a microscope (OLYMPUS, Japan, <https://www.olympusglobal.com>). After the color was completely developed, the sections were rinsed with distilled water or tap water, counterstained with hematoxylin (Wuhan Aspen Biotechnology Co., Ltd. China) differentiated with 1% hydrochloric acid in alcohol (approximately 1 sec), rinsed with tap water until the ammonia water turned blue, and then rinsed with water again. The sections were dehydrated with an alcohol gradient (Sinopharm Chemical Reagent Co., Ltd., <https://www.sinoreagent.com/>) consisting of 75, 90 and 100%, alcohol (10 min each time) and dried, after which they were treated with transparent xylene (Sinopharm Chemical Reagent Co., Ltd., <https://www.sinoreagent.com/>) and neutral gum (Sinopharm Chemical Reagent Co., Ltd., <https://www.sinoreagent.com/>) and sealed. The images were magnified at x400 under a microscope (Olympus, <https://www.olympus-global.com>).

Statistical analysis
--------------------

The quantitative data were analyzed by SPSS 23.0. All the results are expressed as the means ± SD. One-way ANOVA was used to compare the differences among the groups, followed by the LSD post hoc test. A value of P\<0.05 was considered to indicate statistically significant differences. The graphics were designed with GraphPad Prism 7 Software (GraphPad Software Inc., <http://www.graphpad.com/>).

Results
=======

Establishment of NAFLD by feeding C57BL/6J mice an MCD diet
-----------------------------------------------------------

After 4 weeks, the livers from the *C57BL/6J* mice fed an MCD diet were examined by H&E staining, which revealed an increase in steatosis and inflammatory cell infiltration in the MCD *C57BL/6J* group compared with the normal group, and the normal structure of the hepatic lobules was disordered. However, hepatic fibrosis was not observed. After continuously feeding the mice an MCD diet until they reached 19 weeks of age, hepatic fibrosis was not observed ([Fig. 3](#f3-ijmm-44-06-2201){ref-type="fig"}).

Expression of miR-21 is significantly increased in C57BL/6J mice fed an MCD diet
--------------------------------------------------------------------------------

After feeding the mice the MCD diet, the expression of *miR-21* in the livers of mice in each group was detected, and *miR-21* expression was markedly increased in the mice fed the MCD diet (control group) compared with that in the MCS group (normal group) at 19 weeks of age. Furthermore, antagomir-21 was injected via the tail vein, and the level of *miR-21* in the livers of the mice was markedly lower than that in the control group ([Fig. 4A](#f4-ijmm-44-06-2201){ref-type="fig"}). In addition, hepatic steatosis and inflammation in the mice fed the MCD and injected with antagomir-21 ([Fig. 4C](#f4-ijmm-44-06-2201){ref-type="fig"}) were significantly reduced compared with the control group ([Fig. 4D](#f4-ijmm-44-06-2201){ref-type="fig"}).

Inhibition of miR-21 expression improves lipogenesis and transaminase levels in C57BL/6J mice fed an MCD diet
-------------------------------------------------------------------------------------------------------------

In mice fed the MCD diet, the levels of serum lipids (TG, TC and LDL), transaminases (ALT and AST) and genes related to lipid synthesis (*SREBP1c* and *FAS*) were signifi-cantly higher than those in the normal mice fed the MCS diet, while the expression of genes related to lipid oxidation (*AMPKα* and *CPT1α*) in the MCD group was relatively lower than that in the normal group. Following the injection of antagomir-21, the blood lipid and transaminase levels were improved, the expression of lipid synthesis-related genes was inhibited, however, the expression of lipid oxidation genes was increased ([Figs. 5](#f5-ijmm-44-06-2201){ref-type="fig"} and [6](#f6-ijmm-44-06-2201){ref-type="fig"}).

Inhibition of MIR-21 expression activates the WNT/β-catenin signaling pathway in NAFLD
--------------------------------------------------------------------------------------

To validate the regulatory role of *miR-21* in the WNT signaling pathway in mice with NAFLD, antagomir-21 was injected via the tail vein into mice fed the MCD diet, and the same amount of saline was used as a control. Western blot analysis and immunohistochemical staining were used to detect the expression of classical WNT/β-catenin signaling pathway-related proteins in the liver. By inhibiting the expression of *miR-21*, the protein levels of LRP6 were increased compared to those in the control group. Moreover, the expression of glycogen synthase kinase-3β (GSK3β), a downstream degradation complex protein, was reduced, and the accumulation of β-catenin was increased in the cytoplasm. Furthermore, the activity of PPAR-γ, a downstream target of the WNT/β-catenin signaling pathway, was not inhibited following the activation of the WNT signaling pathway, but was in fact increased ([Figs. 7](#f7-ijmm-44-06-2201){ref-type="fig"} and [8](#f8-ijmm-44-06-2201){ref-type="fig"}).

Discussion
==========

The MCD diet has commonly been used for the establishment of NAFLD models, and steatosis and steatohepatitis are usually evident after feeding for 4 weeks ([@b17-ijmm-44-06-2201]). Due to the simplicity and rapid development of the MCD model, we used the MCD diet to establish a NAFLD model, and we observed evidence of NAFLD in our experiments. As one of the miRNAs associated with the pathogenesis and progression of NAFLD, *miR-21* has exhibited alterations in its expression associated with NAFLD. Ahn *et al* found that the expression level of *miR-21* in the livers of mice with steatosis induced by a high-fat diet (49.29% of total fat calories) was lower than that in the control group, and that the expression of *miR-21* was also downregulated *in vitro* by cultivating Hepa 1-6 cells in saturated fatty acids, including stearic acid (SA) ([@b8-ijmm-44-06-2201]), and this is consistent with the results observed in insulin-resistant and diabetic mice with NAFL induced by a high-fat diet ([@b18-ijmm-44-06-2201]) and in patients with NAFLD ([@b9-ijmm-44-06-2201]). However, other studies have demonstrated that serum *miR-21* levels in patients with NAFL are significantly higher than those in healthy individuals and are increased with the increasing severity of fatty liver, although the correlation has not been found to be statistically signifi-cant ([@b19-ijmm-44-06-2201]). A previous study by Becker *et al* found that there was no significant difference in the expression of *miR-21* in serum from patients with NAFL and healthy individuals ([@b20-ijmm-44-06-2201]). In this study, we established a model of NAFLD by feeding *C57BL/6J* mice an MCD diet and found that the expression of *miR-21* in the liver was increased by \~3-fold compared to that in the liver in the normal group that was fed the MCS diet. The discrepancy in the expression of *miR-21* in different research models of NAFLD could be explained by the experimental results of Loyer *et al*, who found that *miR-21* was mainly expressed in inflammatory cells and bile duct cells, but was not expressed as much in the liver ([@b10-ijmm-44-06-2201]).

In the model of NAFLD in this study, the livers of mice exhibited evidence of steatosis, the infiltration of inflammatory cells and damage to hepatocytes. The inhibition of *miR-21* expression in mice alleviated steatosis and inflammation due to NAFLD, which is consistent with other research results ([@b10-ijmm-44-06-2201],[@b21-ijmm-44-06-2201]). Transaminase and lipid levels in the blood were also improved, and the expression of lipid metabolism genes was also ameliorated following the inhibition of *miR-21*. Antagomir-21 could be used as a treatment method. Thus far, whether therapy targeting *miR-21* can alleviate liver fibrosis has not yet been determined. *miR-21* may participate in the process of liver fibrosis through its effects on multiple targets by inhibiting SMAD7 via the TGF-β/SMAD7 signaling pathway ([@b11-ijmm-44-06-2201]) and activating the extracellular signal-regulated kinase 1 (ERK1) signaling pathway by inhibiting SPROUTY2 (SPRY2) to promote epithelial-to-mesenchymal transition (EMT) ([@b22-ijmm-44-06-2201]). However, the results from the study by Caviglia *et al* demonstrated that the inhibition of *miR-21* did not prevent the development of liver fibrosis ([@b23-ijmm-44-06-2201]).

LRP6 participates in the endocytosis of lipoproteins ([@b6-ijmm-44-06-2201]). It has been recognized that the dysfunction of LRP6, such as that caused by the LRP6 gene mutation LRP6^R611C^ (R611C: rs121918313), is involved in dyslipidemia and NAFLD. LRP6^R611C^ mice exhibit hyperlipidemia and liver lipid accumulation, lipid synthesis genes, such as *SREBP1c* and *SREBP2*, and regulated downstream lipases, including acetyl coenzyme A carboxylase, *FAS*, *SCD1*, diglyceryl transferase 1 and the elongation of very long chain fatty acids \[fatty acid elongase (*ELOVL*)\] family members, are increased in LRP6^R611C^ mice ([@b6-ijmm-44-06-2201]). Similarly, Montazeri-Najafabady *et al* recently demonstrated that the LRP6^V1062I^ polymorphism (V1062I: rs2302685) was associated with an increased risk of hyperlipidemia in Iranian children and adolescents, which also increased the risk of elevated total cholesterol, TG, LDL and non-HDL levels ([@b24-ijmm-44-06-2201]). By using rmWnt3a, the blood lipid levels of LRP6^R611C^ mice and the enzymes involved in lipid *de novo* synthesis can be normal-ized ([@b25-ijmm-44-06-2201]). These results indicate that LRP6 can be utilized as a therapeutic target for the treatment of NAFLD by regulating the WNT/β-catenin signaling pathway. In a previous study by our group, the overexpression of *miR-21* in hepatocytes inhibited the expression of LRP6 ([@b14-ijmm-44-06-2201]). In the mouse experiments in this study, we observed that LRP6 expression was increased, which activated the WNT/β-catenin signaling pathway, decreased the degradation of β-catenin and caused more β-catenin to translo-cate to the nucleus to regulate the expression of target genes, such as PPAR-γ, following the inhibition of the expression of *miR-21* in the livers of mice ([Fig. 1](#f1-ijmm-44-06-2201){ref-type="fig"}). However, in contrast to previous research ([@b6-ijmm-44-06-2201]), in this study, the level of PPAR-γ was increased compared with that in the control group. This may be related to the regulation of *miR-21*. Some studies have shown that PPAR-γ is negatively associated with the expression of *miR-21* ([@b18-ijmm-44-06-2201]), however, whether it is a target of *miR-21* has yet to be determined. PPAR-γ can induce preadipocyte differentiation, promote adipo-genesis, induce adipocytes to absorb and store free fatty acids, and promote the transfer of liver fat to adipocytes, at the same time, PPAR-γ activation alleviates inflammation via its negative interaction with nuclear factor-κB (NF-κB) and signal transducer and activator of transcription (STAT), and promotes macrophage cell transition to M2 to inhibit the development of NAFLD ([@b26-ijmm-44-06-2201]), for example, the agonist, rosiglitazone, has been shown to prevent NASH progression in animal models induced by dietary methionine choline deficiency. The antagonistic expression of *miR-21* may alleviate NASH steatosis and inflammation by regulating the WNT/β-catenin signaling pathway in addition to negatively regulating other targets, such as PPAR-α ([@b10-ijmm-44-06-2201]).

In addition to PPAR-γ, *miR-21* may also regulate *SREBP1c* via the WNT signaling pathway. *SREBP1c* promotes the *de novo* synthesis of fat and adipogenesis. *SREBP1/2* is normally retained in the endoplasmic reticulum through Insig1 and Insig2, activated by AKT, transported to the Golgi apparatus via SREBP cleavage-activating protein (*SCAP*) to induce protein hydrolysis and maturation, and then ectopically transferred to the nucleus, in which it binds to target genes ([@b25-ijmm-44-06-2201]). *miR-21* regulates the expression of *SREBP1c* through the *Hbp1-p53-Srebp1c* pathway ([@b13-ijmm-44-06-2201]). LRP6^R611C^ also participates in the progression of NAFLD through the nutritional *IGF1-AKT-mTOR-SREBP1/2* pathway. In this study, we also verified the expression of *SREBP1c* and the expression level of the downstream target, *FAS*. After *miR-21* expression was reduced, LRP6 was activated, and *SREBP1c* was inhibited. The expression levels of the *CPT1α* and *AMPKα* genes, which are related to lipolysis, were increased, and thereby NAFLD was attenuated. Therefore, *miR-21* can regulate the expression of *SREBP1c*-related lipid metabolism genes through the WNT/β-catenin signaling pathway. Due to limited funding, this study did not examine the effects of inhibiting *miR-21*, while antagonizing LRP6 expression or activating LRP6 expression with other drugs in NAFLD. Simultaneously, if *miR-21* knockout mice can be used instead of *miR-21* inhibitors to treat mice, perhaps better results would be obtained.

Further limitations to this study include the small numbers of mice, the simple design of the experiment and the lack of an appropriate control. However, in spite of these, this study demonstrates that the inhibition of *miR-21* expression in mice attenuated NASH steatosis and inflammation, partly by targeting the coreceptor LRP6 and activating the WNT/β-catenin signaling pathway. This finding was consistent with that of a previous cell study ([@b14-ijmm-44-06-2201]), which further supported our hypothesis that *miR-21* may participate in the pathogenesis of NAFLD via its regulation of the WNT/β-catenin signaling pathway; this has enriched our understanding of the molecular mechanisms of *miR-21* in NAFLD. This finding also supported the possibility of inhibiting *MIR-21* expression as a treatment for NAFLD. Due to the complexity of the pathogenesis of NAFLD and the influence of lifestyle habits, single-target therapy has not achieved satisfactory results. miRNAs have multitarget characteristics and can be regulated by multiple miRNAs. Although the inhibition of *miR-21* alone may not achieve satisfactory results, the targeting of *miR-21* could also enhance the therapeutic efficacy of other drugs, such as a combination of *miR-21* and the farne-soid X receptor (FXR) agonist obeticholic acid ([@b21-ijmm-44-06-2201]), and the complex molecular mechanism network underlying the involvement of *miR-21* in NAFLD warrants further investigation. In the future, multitarget drug combinations may become an option for NAFLD treatment.

Not applicable.
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:   fatty acid elongase

NF-κB

:   nuclear factor-κB

STAT

:   signal transducer and activator of transcription

SCAP

:   SREBP cleavage-activating protein

FXR

:   farnesoid X receptor
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![Schematic diagram of the mechanisms of action of *miR-21* showing the regulation of the WNT signaling pathway in NAFLD mice. Red arrows represent inhibition, green arrows represent promotion, and the yellow line represents migration from the cytoplasm into the nucleus When the classical WNT/β-catenin signal is activated, the expression of PPAR-γ is inhibited; however, our experimental results were reversed, and thus, we do not know association between PPAR-γ and the WNT/β-catenin signaling pathway. Thus, due to this uncertainty, question marks (???) were added next to PPAR-γ in the figure. NAFLD, non-alcoholic fatty liver disease; GSK3β, glycogen synthase kinase-3β; LRP6, low-density lipoprotein-related receptor 6; SREBP1/2, sterol regulatory element-binding transcription factor 1/2; IGF1, insulin-like growth factor 1; mTOR, mammalian target of rapamycin.](IJMM-44-06-2201-g00){#f1-ijmm-44-06-2201}

![Mouse study design. MCD, methionine- and choline-deficient, MSC, methionine- and choline-sufficient.](IJMM-44-06-2201-g01){#f2-ijmm-44-06-2201}

![NAFLD was established by feeding an MCD diet to *C57BL/6J* mice. H&E staining at 11 (H&E, x200 magnification) and 19 weeks of age (H&E, x100 magnification). The black arrows indicate steatosis, and the green arrow indicates inflammatory cell infiltration. NAFLD, non-alcoholic fatty liver disease.](IJMM-44-06-2201-g02){#f3-ijmm-44-06-2201}

![Expression of *miR-21* and H&E staining in the liver following the injection of antagomir-21 into *C57BL/6J* mice. (A) Expression of *miR-21* in each group of mice; (B) NAS scoring of the liver sections. (C) Antagomir-21 group H&E staining of the livers of the mice at 19 weeks of age (H&E, x100 magnification). (D) Control group H&E staining of the livers of the mice at 19 weeks of age (H&E, x100 magnification). ^\*^P\<0.05.](IJMM-44-06-2201-g03){#f4-ijmm-44-06-2201}

![Serum lipid and transaminase levels changed following the injection of antagomir-21 into *C57BL/6J* mice. The (A) serum ALT, (B) AST, (C) TG, (D) TC, and (E) LDL levels were reduced following the injection of antagomir-21. ^\*^P\<0.05. ALT, alanine aminotransferase; AST, aspartate aminotransferase; TG, triglycerides; TC, total cholesterol; LDL, low-density lipoprotein.](IJMM-44-06-2201-g04){#f5-ijmm-44-06-2201}

![The mRNA levels of lipid metabolism-related genes following the injection of antagomir-21 into the livers of *C57BL/6J* mice. (A-D) *SREBP1c*, *FAS*, *AMPKα* and *CPT1α* mRNA levels were ameliorated in *C57BL/6J* mice fed an MCD diet following the injection of antagomir-21 compared to the control mice injected with saline. ^\*^P\<0.05. *SREBP1c*, sterol regulatory element-binding transcription factor 1C; FAS, fatty acid synthase; *AMPKα*, adenosine 5-monophos-phate (AMP)-activated protein kinase α; *CPT1α*, carnitine palmitoyl transferase 1α.](IJMM-44-06-2201-g05){#f6-ijmm-44-06-2201}

![Regulatory effects of *mi-21* on the WNT/β-catenin signaling pathway in NAFLD. Western blot analysis was performed to compare protein levels. (A) The levels of LRP6 protein were inhibited in mice fed the MCD diet, which was upregulated by antagomir-21. (B) Protein levels of GSK3β were higher in the control group and lower in the antagomir-21 group. (C) Protein levels of p-β-catenin were lower in the control group and higher in the antagomir-21 group. (D) Protein levels of β-catenin were lower in the control group and higher in the antagomir-21 group. (E) Protein levels of PPAR-γ were lower in the control group and higher in the antagomir-21 group. (F) Expression levels of LRP6, pβ-catenin, β-catenin, PPAR-γ were inhibited, and the expression of GSK3β was increased in mice fed the MCD diet; antagomir-21 administration exerted opposite effects. ^\*^P\<0.05. NAFLD, non-alcoholic fatty liver disease; MCD, methionine and choline-deficient; GSK3β, glycogen synthase kinase-3β; LRP6, low-density lipoprotein-related receptor 6; PPAR-γ, peroxisome proliferator-activated receptor γ.](IJMM-44-06-2201-g06){#f7-ijmm-44-06-2201}

![Immunohistochemical results for the WNT signaling pathway. The expression levels of (A) LRP6, (B) GSK3β, (C) p-β-catenin, (D) β-catenin and (E) PPAR-γ were detected by immunohistochemical staining in the normal group, control group and antagomir-21 group.](IJMM-44-06-2201-g07){#f8-ijmm-44-06-2201}

###### 

Details of primary antibodies used in western blot analysis.

  Name of first antibody   Origin   Manufacturer                Cat. no.   Dilution method      Dilution ratio
  ------------------------ -------- --------------------------- ---------- -------------------- ----------------
  GAPDH                    Rabbit   Abcam                       ab37168    5% evaporated milk   1:10,000
  LRP6                     Rabbit   Abcam                       ab134146   5% evaporated milk   1:500
  GSK3β                    Mouse    Abcam                       ab93926    5% evaporated milk   1:1,000
  p-β-catenin              Rabbit   Cell Signaling Technology   \#4176     5% BSA               1:1,000
  β-catenin                Rabbit   Abcam                       ab32572    5% evaporated milk   1:3,000
  PPAR-γ                   Rabbit   Abcam                       ab209350   5% evaporated milk   1:500

GAPDH, glyceraldehyde-3-phosphate dehydrogenase; LRP6, low-density lipoprotein-related receptor 6; GSK3β, glycogen synthase kinase-3β; PPAR-γ, peroxisome proliferator activated receptor γ.

###### 

Details of secondary antibodies used in western blot analysis.

  Name of secondary antibody   Manufacturer   Cat. no.   Dilution method      Dilution ratio
  ---------------------------- -------------- ---------- -------------------- ----------------
  HRP-goat anti rabbit         KPL            074-1506   5% evaporated milk   1:10,000
  HRP-goat anti mouse          KPL            074-1806   5% evaporated milk   1:10,000

###### 

Sequences of mouse primers used for RT-qPCR.

  Primer name     Primer sequence                                         Product length (bp)
  --------------- ------------------------------------------------------- ---------------------
  M-GAPDH                                                                 
   Forward        5′-TGAAGGGTGGAGCCAAAAG-3′                               227
    Reverse       5′-AGTCTTCTGGGTGGCAGTGAT-3′                             
  M-SREBP-1c                                                              
    Forward       5′-ACAGACAAACTGCCCATCCA-3′                              223
    Reverse       5′-GCAAGAAGCGGATGTAGTCG-3′                              
  M-FAS                                                                   
    Forward       5′-ATCTGGGCTGTCCTGCCTCT-3′                              116
    Reverse       5′-TTATCAGTTTCACGAACCCGC-3′                             
  M-AMPKα                                                                 
    Forward       5′-GATGATGACCATGTGCCAACTC-3′                            270
    Reverse       5′-CTCCGAACACTCGAACTTCTCAC-3′                           
  M-CPT1α                                                                 
    Forward       5′-CATGATTGCAAAGATCAATCGG-3′                            141
    Reverse       5′-AGCACCTTCAGCGAGTAGCG-3′                              
  U6                                                                      
    RT-primer     5′-AACGCTTCACGAATTTGCGT-3′                              
    Forward       5′-CTCGCTTCGGCAGCACAT-3′                                
    Reverse       5′-AACGCTTCACGAATTTGCGT-3′                              
  *mmu-miR-21*                                                            
    *RT-primer*   *5\'-CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGTCAACATC-3′*   
    Forward       5′-ACGGCTTATCAGACTGATGTTGA-3′                           
    Reverse       5′-CTCAACTGGTGTCGTGGAGTC-3′                             

*GAPDH*, glyceraldehyde-3-phosphate dehydrogenase; *SREBP1-c*, sterol regulatory element-binding transcription factor 1C; *FAS*, fatty acid synthase; *AMPKα*, adenosine 5-monophosphate (AMP)-activated protein kinase α; *CPT1α*, carnitine palmitoyl transferase 1α; *miR-21*, *microRNA-21*.

###### 

Details of the primary antibodies used for immunohistochemistry.

  Name          Species   Manufacturer                Cat. no.     Dilution ratio
  ------------- --------- --------------------------- ------------ ----------------
  LRP6          Goat      Abcam                       ab24386      1:200
  β-catenin     Rabbit    Abcam                       ab32572      1:200
  PPAR-γ        Rabbit    Sanying                     16643-1-AP   1:300
  GSK-3β        Rabbit    Cell Signaling Technology   \#12456S     1:400
  p-β-catenin   Rabbit    Cell Signaling Technology   \#4176       1:100

###### 

Details of the secondary antibodies used for immunohistochemistry.

  Name                           Manufacturer   Cat. no.   Dilution ratio
  ------------------------------ -------------- ---------- ----------------
  HRP-labeled rabbit anti-goat   Aspen          AS-1108    1:200
  HRP-labeled goat anti-rabbit   Aspen          AS-1107    1:200
